The advent of new antiretroviral drugs improved the management of HIV naive patients in terms of efficacy. However, the long term metabolic profile of this drugs has not yet been compared and associations between new antiretrovirals and cardiovascular events remains controversial. Moreover, the better tolerability and easy dosage of this new drugs might hypothetically influence adherence and QOL of HIV patients.
Study Type
OBSERVATIONAL
Enrollment
120
Hospital Carlos III
Madrid, Spain
RECRUITINGlipid profile defined as a clinically significant increment (delta) in Total cholesterol LDL, HDL y non-LDL cholesterol.
Time frame: baseline and week 12, 24, 36 and 48
Insulin resistance defined by HOMA index.
Time frame: baseline and week 12, 24, 36 and 48
Cardiovascular biomarkers: ICAM, VICAM, IL-6, PCR hs...
Time frame: baseline and week 12, 24, 36 and 48
Antiretroviral adherence and quality of life items.
Time frame: baseline and week 12,24,36,48
Efficacy defined as viral suppression and CD4 count recovery
Time frame: baseline and week 12,24,36,48
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.